Zosano Pharma Announces US Patent Office Publication of “Method of Rapidly Achieving Therapeutic Concentrations of Triptans...
August 28 2017 - 8:30AM
Zosano Pharma Corporation (NASDAQ:ZSAN) a clinical stage
biopharmaceutical company focused on providing systemic
administration of therapeutics to patients using our proprietary
Adhesive Dermally-Applied Microarray (ADAM) technology, announced
today it has received notification that the US Patent Application
(US 15/438,455) was published by the US Patent Office, on August
24, 2017. The application was originally filed on February
21, 2017.
The patent invention has currently pending claims drawn to M207,
a system for delivering zolmitriptan for the treatment of migraine
using our ADAM technology. The disclosure claims a method for
treatment or alleviation of migraine in a patient, comprising
intracutaneous administration of a therapeutically effective amount
of zolmitriptan that produces a therapeutic concentration of
zolmitriptan in the bloodstream that is faster than therapeutically
effective doses administered orally, intranasally, sublingually, or
iontophoretically. Application of M207 results in zolmitriptan
plasma Tmax as fast as 2 minutes and not later than approximately
30 minutes in most subjects. Furthermore, a significant number of
patients experience pain freedom after about 1 hour
post-application and are free of most bothersome symptoms after
about 2 hours post-application.
"The publication of our patents covering the use of our ADAM
technology with zolmitriptan, which produces a unique
pharmacokinetic profile, is an important step in establishing a
long-term proprietary position for M207. If issued, these
patents would enable M207 to benefit from patent protection through
2037," said John Walker, President and CEO of Zosano Pharma. "This
is also an important step as we evaluate other compounds that can
be delivered with our ADAM technology. If these patents
issue, we can follow a similar strategy with additional molecules
to establish long-term patent protection for future products."
About M207M207 is our proprietary formulation
of zolmitriptan delivered utilizing Zosano's proprietary Adhesive
Dermally-Applied Microarray, or ADAM technology. Zosano's
ADAM technology consists of titanium microprojections coated with
drug, and in the case of M207, our formulation of
zolmitriptan. Our ADAM technology delivers drug by abrading
the stratum corneum and allowing drug to be absorbed into the
microcapillary system of the skin. In February 2017, the
Company announced statistically significant results from the ZOTRIP
trial, which demonstrated that the 3.8mg dose of M207 met both
co-primary endpoints, achieving pain freedom and most bothersome
symptom freedom at 2 hours.
About Zosano PharmaZosano Pharma Corporation is
a clinical stage biopharmaceutical company focused on providing
systemic administration of therapeutics to patients using our
proprietary Adhesive Dermally-Applied Microarray, or ADAM
technology. The Company recently announced positive results
from our ZOTRIP study that evaluated M207, which is our proprietary
formulation of zolmitriptan delivered via our ADAM technology, as
an acute treatment for migraine. Zosano is focused on
developing products where rapid administration of established
molecules with known safety and efficacy profiles provides an
increased benefit to patients, for markets where patients remain
underserved by existing therapies. The Company anticipates that
many of its current and future development programs may enable the
Company to utilize a regulatory pathway that would streamline
clinical development and accelerate the path towards
commercialization. Learn more at www.zosanopharma.com.
Forward-Looking StatementsThis press release
contains forward-looking statements regarding the timing of
expected clinical development milestones, sufficiency of our
capital resources and need for future funding and other future
events and expectations. Readers are urged to consider statements
that include the words "may," "will," "would," "could," "should,"
"might," "believes," "estimates," "projects," "potential,"
"expects," "plans," "anticipates," "intends," "continues,"
"forecast," "designed," "goal," "unaudited," "approximately" or the
negative of those words or other comparable words to be uncertain
and forward-looking. These statements are subject to risks and
uncertainties that are difficult to predict and actual outcomes may
differ materially. These include risks and uncertainties, without
limitation, associated with the process of discovering, developing
and commercializing products that are safe and effective for use as
human therapeutics, risks inherent in the effort to build a
business around such products and other risks and uncertainties
described under the heading “Risk Factors” in the Company’s most
recent annual report on Form 10-K.. Although we believe that the
expectations reflected in these forward-looking statements are
reasonable, we cannot in any way guarantee that the future results,
level of activity, performance or events and circumstances
reflected in forward-looking statements will be achieved or occur.
All forward-looking statements are based on information currently
available to Zosano and Zosano assumes no obligation to update any
such forward-looking statements.
Zosano Contact:
Georgia Erbez
Chief Business Officer and
Chief Financial Officer
510-745-1200
Investor Contact:
Jamien Jones
Blueprint Life Science Group
415-375-3340 x 5
jjones@bplifescience.com
Zosano Pharma (NASDAQ:ZSAN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Zosano Pharma (NASDAQ:ZSAN)
Historical Stock Chart
From Apr 2023 to Apr 2024